Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages

  Komaki, Ritsuko ^a   Paulus, Rebecca ^b   Ettinger, David S ^c   Videtic, Gregory M M ^d   Bradley, Jeffrey D ^e   Glisson, Bonnie S ^a   Langer, Corey J ^f   Sause, William T ^g   Curran Jr , Walter J ^h   Choy, Hak ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g LDS HOSPITAL   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cisplatin; Concomitant boost thoracic radiation; Etoposide; Limited stage small cell lung cancer

Indexed keywords

ACUTE ESOPHAGITIS; CHEMORADIATION; CIS-PLATIN; COMPLETE RESPONSE; CONCURRENT CHEMOTHERAPY; CONFIDENCE INTERVAL; CRANIAL IRRADIATION; ESOPHAGITIS; ETOPOSIDE; EVALUATION CRITERIA; HIGH DOSE; LIMITED-STAGE SMALL-CELL LUNG CANCERS; LOCAL CONTROL; MEDIAN SURVIVAL; OVERALL SURVIVAL RATES; PARTIAL RESPONSE; PERFORMANCE STATUS; PHASE II; PROGRESSION FREE SURVIVAL; PROGRESSIVE DISEASE; RADIATION THERAPY ONCOLOGY GROUPS; SMALL-CELL LUNG CANCER; SOLID TUMORS;

CHEMOTHERAPY; DISEASES; IRRADIATION; ONCOLOGY; PLATINUM COMPOUNDS;

RADIOTHERAPY;

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; BRAIN RADIATION; CANADA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGITIS; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84862698258     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.075     Document Type: Article

References (17)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
2. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 1983;43:2806-2811.
3. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimens in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672.
4. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624.
5. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-895.
6. Pijls-Johannesma MC, De Ruysscher D, Lambin P, et al. Early vs late chest radiotherapy for limited stage small-cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004700.
7. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837-4845.
8. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543-552.
9. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271.
10. Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3528-3536.
11. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: RTOG protocol 97-12. Int J Radiat Oncol Biol Phys 2005;62:342-350.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
13. Fleming T. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957;53:457-482.
15. Werner-Wasik M,Yorke E, Deasy J, et al. Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys 2010;76(3 suppl):S86-S93.
16. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-344.
17. Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900.